Core Viewpoint - 华检医疗's stock price increased by over 16%, reaching 9.64 HKD, with a trading volume of 29.15 million HKD, following the announcement of a board meeting scheduled for August 29, 2025, to discuss mid-term performance and potential dividend payments [1] Group 1 - The company has launched several key strategic initiatives since late July, including the introduction of the "NewCo+RWA" exchange strategy and the issuance of IVDD stablecoins [1] - The company is pushing its U.S. subsidiary to apply for a stablecoin license and has partnered with BGI's subsidiary to establish the world's first "Innovative Drug Intellectual Property Tokenization Fund" [1] - On August 8, the company announced the launch of a "Global Enhanced Ethereum (ETH) Treasury" strategy and completed the compliant purchase of 149 million HKD in ETH in collaboration with licensed exchange HashKey [1] Group 2 - The company is seeking shareholder approval for a 3 billion HKD ETH purchase authorization to provide value anchoring and revenue feedback mechanisms for the medical innovative drug RWA trading platform ecosystem [1]
华检医疗午后涨超16% 公司今日将发布中期业绩 近期连续推出多项关键战略举措